Insider Selling: AcelRx Pharmaceuticals Director Sells 128,780 Shares of Stock (ACRX)
AcelRx Pharmaceuticals (NASDAQ:ACRX) Director Guy Nohra sold 128,780 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $10.42, for a total transaction of $1,341,887.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from $11.00 to $13.00 in a research note to investors on Tuesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from $13.00 to $14.00 in a research note to investors on Tuesday, August 13th. They now have a “buy” rating on the stock. Finally, analysts at Mizuho raised their price target on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from $13.00 to $18.00 in a research note to investors on Wednesday, July 17th. They now have a “neutral” rating on the stock.
One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. AcelRx Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $14.17.
AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 1.82% on Wednesday, hitting $10.24. 545,655 shares of the company’s stock traded hands. AcelRx Pharmaceuticals has a 1-year low of $2.27 and a 1-year high of $13.50. The stock has a 50-day moving average of $10.49 and a 200-day moving average of $8.35. The company’s market cap is $431.3 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings data on Monday, August 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $1.73 million. During the same quarter last year, the company posted ($0.35) earnings per share. Analysts expect that AcelRx Pharmaceuticals will post $-1.07 EPS for the current fiscal year.
AcelRx Pharmaceuticals, Inc is a development-stage company. The Company is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.